In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 2148-2157

  Sharma, Raman ^a   McDonald, Thomas S ^a   Eng, Heather ^a   Limberakis, Chris ^a   Stevens, Benjamin D ^a   Patel, Sheena ^a   Kalgutkar, Amit S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 (29-36) AMIDE; GLUCAGON LIKE PEPTIDE 1 (31-36) AMIDE; GLUCAGON LIKE PEPTIDE 1 [28-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; PHOSPHORAMIDON; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; GLUCONEOGENESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN STABILITY; TANDEM MASS SPECTROMETRY;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; GLUCONEOGENESIS; HEPATOCYTES; HUMANS; MICE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS;

EID: 84888581721     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054254     Document Type: Article

References (40)

1. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, and Elahi D (2009) Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94:1843-1852.
2. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, and Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1receptor-dependent and independent pathways. Circulation 117:2340-2350.
3. Elovson J (1980) Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins. J Biol Chem 255:5807-5815.
4. Deacon CF, Johnsen AH, and Holst JJ (1995a) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957.
5. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131.
6. Deacon CF, Pridal L, Klarskov L, Olesen M, and Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464.
7. Edwards CM (2013) Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. Br J Hosp Med (Lond) 74:198-201.
8. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, and Anderson DK (2008) Glucagon-like peptide-1 (9-36) amide, cleavage product of glucagon-like peptide-1 (7-36) is a glucoregulatory peptide. Obesity (Silver Spring) 16:1501-1509.
9. Gandhi CR, Harvey SA, and Olson MS (1993) Hepatic effects of endothelin: metabolism of [125I]endothelin-1 by liver-derived cells. Arch Biochem Biophys 305:38-46.
10. Hansen L, Deacon CF, Orskov C, and Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363.
11. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439.
12. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
13. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, and Voigt K (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149-156.
14. Itou M, Kawaguchi T, Taniguchi E, and Sata M (2013) Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 19:2298-2306.
15. Kieffer TJ and Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913.
16. Liu Z, Stanojevic V, Brindamour LJ, and Habener JF (2012) GLP1-derived nonapeptide GLP1 (28-36)amide protects pancreatic β-cells from glucolipotoxicity. J Endocrinol 213:143-154.
17. Lovshin JA and Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269.
18. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, and Olsen AK (2010) Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 38:1944-1953.
19. Medzihradszky KF (2005) Peptide sequence analysis. Methods Enzymol 402:209-244.
20. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
21. Mentlein R, Gallwitz B, and Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835.
22. Moore KB and Saudek CD (2008) Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. Am J Ther 15:484-491.
23. Mundil D, Cameron-Vendrig A, and Husain M (2012) GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 9:95-108.
24. Nikolaidis LA, Elahi D, Shen YT, and Shannon RP (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2401-H2408.
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
26. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, and Coe JW (2006) Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121-130.
27. Roden M, Prskavec M, Fürnsinn C, Schneider B, Waldhäusl W, and Vierhapper H (1994) Evidence for phosphoramidon-sensitive cleavage of big endothelin-1 involved in endothelin-stimulated hepatic glucose production. Regul Pept 51:207-213.
28. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, and Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146.
29. Senafi SB, Clarke DJ, and Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP- glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303:233-240.
30. Sonne DP, Engstrøm T, and Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243-249.
31. Thorens B (1992) Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645.
32. Toide K, Terauchi Y, Fujii T, Yamazaki H, and Kamataki T (2004) Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochem Pharmacol 67:1269-1278.
33. Tomas E and Habener JF (2010) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21:59-67.
34. Tomas E, Stanojevic V, and Habener JF (2010) GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 42:657-662.
35. Tomas E, Stanojevic V, and Habener JF (2011b) GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 167:177-184.
36. Tomas E, Wood JA, Stanojevic V, and Habener JF (2011a) GLP-1-derived nonapeptide GLP-1 (28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regul Pept 169:43-48.
37. Turner AJ, Isaac RE, and Coates D (2001) The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23:261-269.
38. Ura N, Carretero OA, and Erdös EG (1987) Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32:507-513.
39. Wysocki VH, Resing KA, Zhang Q, and Cheng G (2005) Mass spectrometry of peptides and proteins. Methods 35:211-222.
40. Yasojima K, Akiyama H, McGeer EG, and McGeer PL (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci Lett 297:97-100.